IBRX
ImmunityBio, Inc. · Healthcare · Biotechnology
$10.28
+10.83% today · +21.86% 1W
Oct 2 close or latest
PreviewWhy it's moving
Outperforming without a clear catalyst yet
- IBRX +10.83% on the last session vs SPY +0.74%: +10.1 pts of stock-specific move.
- Aftermath, rsi overbought (Oct 2): After its 11 overbought readings in the past 5 years, IBRX typically lost 5.3% over the next month (median) and was higher only 45% of the time; half the outcomes fell between -16.9% and +32.6%. An ordinary month: -1.8%. Among S&P 500 stocks after overbought readings, that ranks #263 of 501.
- 0 Reddit mentions in the past 24 hours, 81% positive over the week · today's pace is 1.5× its recent daily average.
- Market backdrop (Fri): Average Hourly Earnings m/m 0.1% vs 0.3% expected (cooler); Non-Farm Employment Change 29K vs 89K expected (weaker); S&P futures +0.41%, 10-year yield -5bp in the 30 minutes after.
Assembled from Wallsti's own signals.
Next report
Nov 3
In 30 days
estimated date
EPS estimate
−$0.05
−$0.09 to $0.00 · 3 analysts
Revenue estimate
$59.2M
$55.6M to $65.9M
Track record
4/8 beats
last 8 reports · moved ±7.9% on average
Reports
| Reported | Quarter | EPS est. | EPS | EPS surprise | Revenue | Reaction | Gap | 5 days |
|---|---|---|---|---|---|---|---|---|
| Aug 4, 2026 BMO | 2Q2026 | −$0.08 | −$0.22 | −$0.14 miss | — | -2.8% -4.6 vs SPY | -5.5% | +4.8% |
| May 7, 2026 BMO | 1Q2026 | −$0.07 | −$0.08 | −$0.01 miss | $44.2M | -7.4% -7.1 vs SPY | -6.7% | -2.7% |
| Feb 23, 2026 BMO | 4Q2025 | −$0.10 | −$0.06 | +$0.04 beat | $38.3M | +13.0% +14.0 vs SPY | +14.4% | +12.4% |
| Nov 4, 2025 AMC | 3Q2025 | −$0.10 | −$0.07 | +$0.03 (+30.0%) beat | $32.1M | +3.4% +3.0 vs SPY | +5.3% | +2.9% |
| Aug 5, 2025 BMO | −$0.10 | −$0.10 | $0.00 (0.0%) in line | — | 0.0% +0.5 vs SPY | -0.4% | +2.5% | |
| May 12, 2025 BMO | −$0.14 | −$0.15 | −$0.01 (−7.1%) miss | — | +14.0% +10.7 vs SPY | +8.9% | +37.2% | |
| Mar 3, 2025 BMO | −$0.13 | −$0.08 | +$0.05 (+38.5%) beat | — | -13.4% -11.6 vs SPY | -2.7% | -8.8% | |
| Nov 12, 2024 BMO | −$0.18 | −$0.12 | +$0.06 (+33.3%) beat | — | -9.2% -8.9 vs SPY | -1.6% | -8.1% | |
| Aug 12, 2024 BMO | −$0.15 | −$0.20 | −$0.05 (−33.3%) miss | — | -2.6% -2.7 vs SPY | -1.1% | -11.7% | |
| May 9, 2024 AMC | −$0.16 | −$0.20 | −$0.04 (−25.0%) miss | — | +0.7% +0.6 vs SPY | -2.2% | -3.9% | |
| Mar 19, 2024 AMC | −$0.18 | −$0.38 | −$0.20 (<−100%) miss | — | +10.3% +9.4 vs SPY | +1.3% | -5.7% | |
| Nov 9, 2023 BMO | −$0.18 | −$0.19 | −$0.01 (−5.6%) miss | — | -17.1% -16.3 vs SPY | -2.3% | +19.2% | |
| Aug 8, 2023 AMC | −$0.23 | −$0.32 | −$0.09 (−39.1%) miss | — | -10.2% -9.6 vs SPY | -0.5% | +5.4% | |
| May 11, 2023 BMO | −$0.27 | −$0.27 | $0.00 (0.0%) in line | — | -55.1% -55.0 vs SPY | -55.7% | -48.1% | |
| Mar 1, 2023 AMC | −$0.16 | −$0.27 | −$0.11 (−68.8%) miss | — | -10.6% -11.3 vs SPY | +1.3% | -28.6% | |
| Nov 9, 2022 BMO | −$0.21 | −$0.28 | −$0.07 (−33.3%) miss | — | -10.7% -8.6 vs SPY | -2.3% | +24.2% | |
| Aug 8, 2022 AMC | −$0.24 | −$0.24 | $0.00 (0.0%) in line | — | -2.9% -2.5 vs SPY | -1.1% | +5.8% | |
| May 10, 2022 AMC | −$0.22 | −$0.26 | −$0.04 (−18.2%) miss | — | -22.3% -20.7 vs SPY | 0.0% | +17.1% | |
| Mar 1, 2022 AMC | −$0.21 | −$0.23 | −$0.02 (−9.5%) miss | — | -1.4% -3.2 vs SPY | +0.3% | -5.5% | |
| Nov 12, 2021 AMC | −$0.20 | −$0.22 | −$0.02 (−10.0%) miss | — | -7.5% -7.5 vs SPY | +1.7% | -16.7% | |
| Aug 12, 2021 AMC | −$0.12 | −$0.23 | −$0.11 (−91.7%) miss | — | — | — | — | |
| May 14, 2021 AMC | −$0.41 | −$0.21 | +$0.20 (+48.8%) beat | — | — | — | — |
BMO = before the open, AMC = after the close. Reaction: the first session that could trade on the report (the same day for BMO, the next session for AMC) against the close before it; "vs SPY" subtracts the S&P 500 over the same session. EPS surprise is in dollars, with the percentage only when the estimate is at least $0.10 (near zero, a small beat would show as hundreds of percent). Revenue surprise needs the estimate from before the report, so it starts with the reports Wallsti saw coming.
Analyst estimates
| Period | EPS | Range | vs year ago | 90-day trend | Revisions 30d | Revenue | vs year ago |
|---|---|---|---|---|---|---|---|
| Current quarter · Sep 30, 2026 | −$0.05 (3) | −$0.09 – $0.00 | +29% | -28.6% | ▲1 ▼0 | $59.2M | +85% |
| Next quarter · Dec 31, 2026 | −$0.04 (3) | −$0.09 – $0.00 | +28% | -13.3% | ▲1 ▼0 | $71.2M | +86% |
| Current year · Dec 31, 2026 | −$0.92 (2) | −$0.93 – −$0.90 | -141% | ▲1 ▼1 | $225.7M | +99% | |
| Next year · Dec 31, 2027 | −$0.14 (2) | −$0.35 – $0.07 | +85% | -333.3% | ▲1 ▼0 | $454.4M | +101% |
Consensus as of Oct 4, 2026. Source: Yahoo Finance analyst estimates; schedule and timing also from Nasdaq's earnings calendar.